INCYHIGH SIGNALFINANCIAL10-K

INCY experienced extraordinary financial performance with net income surging 3,845% to $1.3B while simultaneously taking on $19.1B in new debt.

The dramatic profit increase combined with massive debt accumulation suggests a major corporate transaction or acquisition that fundamentally transformed the company's financial profile. The 5.5 million share increase in outstanding stock and substantial cash position growth to $3.1B further indicate significant corporate activity that requires immediate investor attention.

Comparing 2026-02-10 vs 2025-02-10View on EDGAR →
FINANCIAL ANALYSIS

INCY delivered exceptional financial results with net income exploding from $32.6M to $1.3B (+3,845%) and operating income rising to $1.5B (+2,369%), while operating cash flow increased 322% to $1.4B. The company simultaneously increased total debt from $26.8M to $19.1B, though this was accompanied by cash growing 84% to $3.1B and stockholders' equity expanding 50% to $5.2B. The overall picture suggests a transformative corporate event that dramatically improved profitability while adding substantial leverage, creating both significant opportunities and risks for investors.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
+71146.3%
$26.8M$19.1B

Debt increased 71146.3% — substantial leverage increase; assess whether deployed for growth or covering losses.

Net Income
P&L
+3845%
$32.6M$1.3B

Net income grew 3845% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+2368.6%
$61.4M$1.5B

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+321.5%
$335.3M$1.4B

Operating cash flow surged 321.5% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
+83.5%
$1.7B$3.1B

Cash position surged 83.5% — strong cash generation or capital raise providing significant financial cushion.

Inventory
Balance Sheet
+71.7%
$58.9M$101.1M

Inventory surged 71.7% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+55.1%
$3.2B$5.0B

Current assets grew 55.1% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+49.9%
$3.4B$5.2B

Equity base grew 49.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+27.8%
$5.4B$7.0B

Asset base grew 27.8% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
-21.4%
$2.6B$2.1B

R&D spending cut 21.4% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-10
PRIOR — 2025-02-10
ADDED
As of February 3, 2026 there were 199,014,486 shares of Common Stock, $.001 par value per share, outstanding.
or other government proposals regarding drug pricing; the expected impact of recent accounting pronouncements and changes in tax laws; expected losses; the fluctuation of losses; the currency translation impact associated with non-U.S.
Incyte, JAKAFI, MINJUVI, MONJUVI, OPZELURA, PEMAZYRE and ZYNYZ are our registered trademarks and NIKTIMVO and JAKAFI XR are our trademarks.
Risk Factors of this report before deciding whether to invest in our company.
If we fail to comply with applicable laws and regulations, we could lose our approval to market our products or be subject to other governmental enforcement activity, and we could face increased costs, penalties and a loss of business.
+7 more — sign up free →
REMOVED
As of February 3, 2025 there were 193,524,350 shares of Common Stock, $.001 par value per share, outstanding.
Incyte, JAKAFI, MINJUVI, MONJUVI, OPZELURA, PEMAZYRE and ZYNYZ are our registered trademarks and NIKTIMVO is our trademark.
of this report, Risk Factors, before deciding whether to invest in our company.
If we fail to comply with applicable laws and regulations, we could lose our approval to market our products or be subject to other governmental enforcement activity.
If the use of our products harms or is perceived to harm patients, our regulatory approvals could be revoked or otherwise negatively impacted or we could be subject to costly product liability claims.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →